Current perspectives in the treatment of childhood lichen planus

Childhood lichen planus (CLP) is relatively common in India. With a mean age of onset at 7-8 years, CLP poses a therapeutic challenge as most guidelines for treatment cater to adult lichen planus (LP) with no defined evidence-based recommendations for CLP. Each case of CLP needs customized therapy w...

Full description

Saved in:
Bibliographic Details
Published inIndian journal of paediatric dermatology Vol. 22; no. 4; pp. 316 - 325
Main Authors Mutalik, Sharad, Belgaumkar, Vasudha, Rasal, Yashashree
Format Journal Article
LanguageEnglish
Published Wolters Kluwer India Pvt. Ltd 01.10.2021
Medknow Publications and Media Pvt. Ltd
Wolters Kluwer Medknow Publications
Subjects
adolescent
Care and treatment
children
Evidence-based medicine
Health aspects
Hydrochlorothiazide
Lichen planus
pediatric
Phototherapy
Pimecrolimus
Retinoids
Tetracycline
Tetracyclines
treatment
India
treatment
children
lichen planus
Adolescent
pediatric
Online AccessGet full text

Cover

More Information
Summary:Childhood lichen planus (CLP) is relatively common in India. With a mean age of onset at 7-8 years, CLP poses a therapeutic challenge as most guidelines for treatment cater to adult lichen planus (LP) with no defined evidence-based recommendations for CLP. Each case of CLP needs customized therapy with a step-wise approach. Topical corticosteroids are ably supported by topical calcineurin inhibitors, while oral retinoids, immunosuppressants like cyclosporine, and immunomodulators such as dapsone and narrowband ultraviolet B phototherapy are taking center stage in place of oral corticosteroids as systemic treatment modalities. However, the management of mucosal and appendageal LP requires systemic steroids more often than not. For the present review, we extracted the available data published in the English literature (Google Scholar databases, PubMed, and Medline) using search terms "lichen planus," "treatment," "children," "pediatric," and synthesized documented evidence regarding the risk-benefit profile of each therapeutic modality used in CLP. Undoubtedly, reporting of anecdotal successes, case studies, and conducting randomized controlled trials will help to structure consensus guidelines for the therapeutic conundrum of CLP.
ISSN:2319-7250
2319-7269
DOI:10.4103/ijpd.ijpd_165_20